Spandana Daryani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Spandana Daryani has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Angela J. Jiang
Department of Dermatology Oregon Health & Science University Portland Oregon USA
1 shared publication - Jesse Joel Keller
Department of Dermatology, Oregon Health & Science University, Portland, Oregon
1 shared publication - Jordan Gillespie
Department of Dermatology, Oregon Health & Science University , Portland, OR
1 shared publication - Moira Shea
Department of Dermatology Oregon Health & Science University Portland Oregon USA
1 shared publication - Nicole Fett
Oregon Health and Science University, Portland, Oregon
1 shared publication
Latest Publications
- 11 May 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (10) , 937-940
Generalized Bullous Fixed Drug Eruption due to Clopidogrel Hypersensitivity Successfully Treated Using the Jefferson Procedure
Generalized bullous fixed drug eruption (GBFDE) is a rare variant of fixed drug eruption that is known to clinically mimic Stevens‐Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Numerous medications have been reported to cause GBFDE, including antiplatelet agents like ticagrelor, but few reports exist linking this reaction to clopidogrel specifically. We report a case of a medically complex 80‐year‐old male who was found to have clopidogrel hypersensitivity manifesting as GBFDE based on clinical characteristics and pathology. He was successfully treated using the Jefferson desensitization protocol, which was developed by cardiologists to enable continuation of clopidogrel. While clopidogrel hypersensitivity reactions are well‐reported, there is a shortage of dermatology literature characterizing the clinical characteristics of these rashes and highlighting the use of the Jefferson desensitization protocol. This case reports on an etiology for GBFDE that is rarely observed and emphasizes the importance of histopathology when differentiating this entity from SJS/TEN. It also reports the successful use of the Jefferson protocol for GBFDE secondary to clopidogrel hypersensitivity.
- 11 May 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (10) , 937-940
Generalized Bullous Fixed Drug Eruption due to Clopidogrel Hypersensitivity Successfully Treated Using the Jefferson Procedure
Generalized bullous fixed drug eruption (GBFDE) is a rare variant of fixed drug eruption that is known to clinically mimic Stevens‐Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Numerous medications have been reported to cause GBFDE, including antiplatelet agents like ticagrelor, but few reports exist linking this reaction to clopidogrel specifically. We report a case of a medically complex 80‐year‐old male who was found to have clopidogrel hypersensitivity manifesting as GBFDE based on clinical characteristics and pathology. He was successfully treated using the Jefferson desensitization protocol, which was developed by cardiologists to enable continuation of clopidogrel. While clopidogrel hypersensitivity reactions are well‐reported, there is a shortage of dermatology literature characterizing the clinical characteristics of these rashes and highlighting the use of the Jefferson desensitization protocol. This case reports on an etiology for GBFDE that is rarely observed and emphasizes the importance of histopathology when differentiating this entity from SJS/TEN. It also reports the successful use of the Jefferson protocol for GBFDE secondary to clopidogrel hypersensitivity.